We are live on
!
Find out more
FM
Frazier Management Portfolio holdings
AUM
$1.12M
1-Year Est. Return
151.58%
This Fund
S&P 500
This Quarter
Est. Return
+3.35%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$49.1M
(+3.9%)
Cap. Flow
+$130M
Cap. Flow
% of AUM
10.05%
Top 10 Holdings %
Top 10 Hldgs %
55.9%
Holding
47
New
6
Increased
12
Reduced
2
Closed
4
Avg Time Held
5.9
quarters
Top 10 Avg Time Held
4.4
quarters
Top 20 Avg Time Held
5.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Syndax Pharmaceuticals
SNDX
|
+$29.3M |
| 2 |
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
|
+$28.6M |
| 3 |
Silence Therapeutics
SLN
|
+$20.5M |
| 4 |
KalVista Pharmaceuticals
KALV
|
+$18.3M |
| 5 |
Merus
MRUS
|
+$15.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
+$55M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$20.4M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
+$2.65M |
| 4 |
Galera Therapeutics, Inc. Common Stock
GRTX
|
+$1.95M |
| 5 |
FRLN
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
|
+$1.88M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.85% |
| 2 | Miscellaneous | 1.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Tyra Biosciences
TYRA
$1.28B
| $17.6M | 1.35% |
1,250,000
| – | – |
2021 Q3
1 quarter
|
|
|
27
DELISTED
KalVista Pharmaceuticals
KALV
| $17.3M | 1.33% |
1,305,087
+1,148,280
| +732% | +$18.3M |
2021 Q3
1 quarter
|
|
|
TCDA
28
DELISTED
Tricida, Inc. Common Stock
TCDA
| $17.1M | 1.31% |
+1,783,893
| New | +$11.5M |
2021 Q4
0 quarters
|
|
29
Cogent Biosciences
COGT
$4.87B
| $15.2M | 1.17% |
+1,774,891
| New | +$15.4M |
2021 Q4
0 quarters
|
|
|
FLACU
30
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
| $14.9M | 1.15% |
1,501,000
| – | – |
2020 Q4
4 quarters
|
|
31
Arvinas
ARVN
$447M
| $13.5M | 1.04% |
+163,763
| New | +$13.3M |
2021 Q4
0 quarters
|
|
|
GRCL
32
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $10M | 0.77% |
1,654,938
+803,300
| +94% | +$7.72M |
2021 Q3
1 quarter
|
|
33
DELISTED
ESSA Pharma
EPIX
| $7.72M | 0.59% |
543,470
+185,124
| +52% | +$2.06M |
2021 Q1
3 quarters
|
|
34
Regenxbio
RGNX
$479M
| $7.71M | 0.59% |
235,809
| – | – |
2020 Q3
5 quarters
|
|
|
AVDL
35
DELISTED
Avadel Pharmaceuticals
AVDL
| $7.69M | 0.59% |
951,814
| – | – |
2021 Q1
3 quarters
|
|
36
Aclaris Therapeutics
ACRS
$511M
| $5.94M | 0.46% |
408,329
| – | – |
2021 Q1
3 quarters
|
|
37
DELISTED
Molecular Templates, Inc.
MTEM
| $5.39M | 0.41% |
91,603
| – | – |
2020 Q4
4 quarters
|
|
|
APTX
38
DELISTED
Aptinyx Inc. Common Stock
APTX
| $5.03M | 0.39% |
1,883,244
| – | – |
2018 Q2
14 quarters
|
|
39
Immunovant
IMVT
$5.93B
| $4.99M | 0.38% |
585,759
| – | – |
2021 Q1
3 quarters
|
|
40
Scholar Rock
SRRK
$4.93B
| $3.88M | 0.3% |
156,000
| – | – |
2020 Q4
4 quarters
|
|
|
EPZM
41
DELISTED
Epizyme, Inc
EPZM
| $1.85M | 0.14% |
739,369
| – | – |
2020 Q4
4 quarters
|
|
|
ALNA
42
DELISTED
Allena Pharmaceuticals
ALNA
| $978K | 0.08% |
1,651,357
-1,679,016
| -50% | -$1.31M |
2017 Q4
16 quarters
|
|
|
NBRV
43
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $255K | 0.02% |
17,026
| – | – |
2018 Q3
13 quarters
|
|
|
44
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| – | – |
-241,000
| Closed | -$1.95M | – |
|
|
FRLN
45
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
| – | – |
-36,667
| Closed | -$1.88M | – |
|
|
BLU
46
DELISTED
BELLUS Health Inc.
BLU
| – | – |
-433,247
| Closed | -$2.65M | – |
|
|
TRIL
47
DELISTED
Trillium Therapeutics Inc.
TRIL
| – | – |
-3,123,107
| Closed | -$55M | – |
|
Similar funds
ACMV
FRCMI
DB
NAM
AP
ID
CI
DIF
Frazier Management's Q4 2021 Portfolio in Review
As of Q4 2021, Frazier Management held 47 positions worth $1.3B, up 3.9% from $1.25B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Frazier Management deployed $130M of net new capital in Q4 2021, opening 6 new positions and adding to 12 existing holdings. Its largest new stake was Pardes Biosciences, Inc. Common Stock: 2,457,507 shares worth $40.2M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $20.4M trimmed.
- Frazier Management's largest Q4 2021 buy was Pardes Biosciences, Inc. Common Stock: 2,457,507 shares worth $40.2M.
- Frazier Management added most to Syndax Pharmaceuticals in Q4 2021, an estimated $29.3M increase.
- Frazier Management's biggest Q4 2021 reduction was Iovance Biotherapeutics, cutting an estimated $20.4M.
- Frazier Management fully exited Trillium Therapeutics Inc. in Q4 2021, selling an estimated $55M.
- Frazier Management's ten largest holdings make up 56% of its $1.3B portfolio in Q4 2021.
- Frazier Management opened 6 new positions and closed 4 in Q4 2021.
- Frazier Management's portfolio value rose 3.9% quarter-over-quarter to $1.3B.
Based on Frazier Management's 13F filing for Q4 2021, filed 8 Feb 2022.